English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)

MPS-Authors
/persons/resource/persons78123

Holak,  Tad A.
Holak, Tad / NMR Spectroscopy, Max Planck Institute of Biochemistry, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)

8730-132617-4-PB.pdf
(Publisher version), 4MB

Supplementary Material (public)

8730-132624-1-SP.pdf
(Supplementary material), 3MB

Citation

Zak, K. M., Grudnik, P., Guzik, K., Zieba, B. J., Musielak, B., Domling, A., et al. (2016). Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget, 7(21), 30323-30335. doi:10.18632/oncotarget.8730.


Cite as: https://hdl.handle.net/11858/00-001M-0000-002C-1843-F
Abstract
Targeting the PD-1/PD-L1 immunologic checkpoint with monoclonal antibodies has provided unprecedented results in cancer treatment in the recent years. Development of chemical inhibitors for this pathway lags the antibody development because of insufficient structural information. The first nonpeptidic chemical inhibitors that target the PD-1/PD-L1 interaction have only been recently disclosed by Bristol-Myers Squibb. Here, we show that these small-molecule compounds bind directly to PD-L1 and that they potently block PD-1 binding. Structural studies reveal a dimeric protein complex with a single small molecule which stabilizes the dimer thus occluding the PD-1 interaction surface of PD-L1s. The small-molecule interaction "hot spots" on PD-L1 surfaces suggest approaches for the PD-1/PD-L1 antagonist drug discovery.